Industry landscapes
The companies, capital and talent shaping life sciences in Israel. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
No company example met every recorded classification, independence and public-profile gate in this snapshot. The live directory may have newer qualifying companies.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
44 of 1,143 tracked companies have open roles.
372 of 1,143 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 687 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 14.2% of disclosed capital, while 67.5% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $396.23M | 63 | 62 |
| 2017 | $707.69M | 56 | 58 |
| 2018 | $470.63M | 48 | 65 |
| 2019 | $759.46M | 53 | 69 |
| 2020 | $1.56B | 61 | 73 |
| 2021 | $861.93M | 29 | 60 |
| 2022 | $933.84M | 19 | 44 |
| 2023 | $569.47M | 15 | 37 |
| 2024 | $825.54M | 7 | 39 |
| 2025 | $673.96M | 1 | 27 |
Share of all disclosed company funding.
779 recorded rounds since 2016
Recorded participation in life sciences company rounds since 2016.
Backed by .
Backed by Europa and Junson Capital and others.
Backed by 10D and Entree Capital and others.
Backed by FUSION and GlenRock Israel and others.
Backed by .
Backed by .
Backed by Brainsway.
Backed by .
Backed by Boston Scientific.
Backed by Fidelity Investments and Nexus NeuroTech Ventures and others.
Backed by Koch Disruptive Technologies.
Backed by Elbit Imaging and York Capital Management and others.
Backed by Eclipse and Adani Group and others.
Backed by Battery Ventures and Bessemer Venture Partners and others.
Backed by Koch Disruptive Technologies and Battery Ventures and others.
Backed by Novo Holdings and Viking Global Investors and others.
Backed by Horizons Ventures and Shavit Capital and others.
Backed by CPMG and H.I.G. Capital and others.
No reviewed exact national-ID connector maps Israel company identities to the configured global filings table.; No reviewed exact national-ID connector maps Israel company identities to the configured global filings table.
How the Israel companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
35 of these companies (3.1%) publish at least one Android app — 50 apps in all, carrying 2.9M installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| Walabot DIYWalabot | 1.4M | 4.2 | Productivity |
| WatchPATItamar Medical | 846.9K | 4.7 | Health & Fitness |
| Reimagine: Scan & Enhance PicsMyHeritage | 251.4K | 4.2 | Photography |
| Lumen - Metabolic CoachLumen | 135.6K | 4.3 | Health & Fitness |
| איפה דפי? - מיפוי דפיברילטוריםDefi (Healthcare Technology Systems) | 106.6K | 5 | Medical |
| Woojer Device ManagerWoojer- Born to Feel | 48.4K | 4.7 | Music & Audio |
| HITO Tracer™HITO Systems | 30.4K | — | Business |
| Monitor TotalCareMonitor | 15.2K | — | Medical |
| Biobeat Hospital at Home ChestBiobeat | 7.3K | — | Medical |
| PhenoTopPhenome Networks | 5K | — | Business |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2023Q1–2026Q2).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Wearable Technology | 31 | 1.7M | Walabot DIY 1.4M | |
| Disease Self Management | 29 | 1.7M | Lumen - Metabolic Coach 135.6K | |
| Assistive Tech | 4 | 1.6M | איפה דפי? - מיפוי דפיברילטורים 106.6K | |
| Cardiac And Vascular Disorders | 19 | 877K | WatchPAT 846.9K | |
| Genomics | 3 | 256.6K | Reimagine: Scan & Enhance Pics 251.4K | |
| Fitness & Wellness Tech | 3 | 136.5K | Dormotech 858 | |
| Medical Devices | 2 | 106.6K | Perineal Massage Trainer 3 | |
| Ent Disorders | 3 | 49.7K | Woojer Device Manager 48.4K |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 40 of 50 apps carry a release date. The series ends at 2026Q1, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
32 companies hiring · $9.06B disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
Enlivex’s most recent acquisitions of RAIN tokens were made via partial exercises of the Company’s option to acquire up to 272,121,212,121 RAIN tokens from the Rain Foundation.
BiomX has acquired a majority stake in DFSL, a LADAR-based detection systems manufacturer, from Mandragola in a tech M&A deal valued at $6 million.
Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced it has completed its acquisition of CathWorks, a privately held medical device company, which aims to transform how coronary artery disease (CAD) is diagnosed and treated.
Spanish frozen bakery business Monbake Group has struck a deal to acquire local foodservice supplier Triticum.
Aggregate gross proceeds to the Company from both transactions were approximately $3.5 million. The transactions closed on April 8, 2026.
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it has closed its previously announced offering of an additional debenture of the Company (the "Debenture") to its largest shareholder, Tamar Innovest Ltd. ("Tamar Innovest") for gross proceeds of US $200,000 (the "Offering").
IceCure Medical Ltd. (Nasdaq: ICCM) (...) announced that it has entered into securities purchase agreements with healthcare focused institutional investors for the purchase and sale of 8,000,000 ordinary shares at a purchase price of $0.50 per share in a registered direct offering. The gross proceeds from the offering are expected to be approximately $4.0 million, before deducting placement agent fees and other offering expenses.
OSSIO has closed an initial $40 million senior credit facility, with an additional $10 million available to support future growth, according to Horizon Technology Finance Corporation and Monroe Capital.
The gross proceeds to the Company from the offering are expected to be approximately $4.75 million , before deducting placement agent commissions and other offering expenses.
Haynes Boone represented Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company pioneering oral drug delivery solutions, in its strategic transaction with Lifeward Ltd., a revenue-generating medical robotics company.
Top 10 categories among 547 recorded events in the 24-month window.
19 companies with recorded IPO activity
IPO · NYSE American3 reports
IPO · NYSE American5 reports
Follow-on Offering4 reports
IPO · NASDAQ1 reports
IPO1 reports
IPO · NASDAQ2 reports
Follow-on Offering · Nasdaq3 reports
IPO · NASDAQ2 reports
18 tracked people moves
Departure Previously Board Member
Resignation Previously Chief Financial Officer
Resignation Previously Chief Financial Officer
Departure Previously Director
Appointment Board Member
Appointment Chief Medical Officer
Appointment Vice President of Business Development
Appointment Chairman of the Board of Directors
Products, platforms and features in the recorded window
SaaS
AI-based Solar Forecasting Engine
bioprinted skin model
4 recorded customer wins
Customer: arrow aviationPrivate Aviation
Customer: renovateOphthalmic diagnostics
Customer: LifewardPharmaceuticals
Customer: Technology
1 companies with reported reductions
20 roles
22 recorded events
approved to adopt SARBritish Columbia Securities Commission
approved for domestic useIsraeli MoH
closed the investigationThe Commission
obtained Orphan Drug Designation
2 tracked suits
real estate transaction disputeCivil · Settled
securities law violations / breach of fiduciary dutyRegulatory ·
Reported company results in the recorded window.
Median across 53 reported growth observations; companies may contribute multiple periods.
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| Enlivex Pharmaceuticals→rain foundation | Announced | 2026-04-27 | $898.0M |
| BiomX→DFSL | Announced | 2026-04-22 | $6.0M |
| medtronic→CathWorks ↗ | Completed | 2026-04-20 | $585.0M |
| Monbake Group→Triticum Medical ↗ | Announced | 2026-04-15 | Not stated in snapshot |
| Polyrizon→colugo systems | Announced | 2026-03-24 | $6.0M |
| Polyrizon→arrow aviation | Announced | 2026-02-05 | $5.8M |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
Recorded hiring and workforce signals from the available source snapshot.
No repeated job title is supported by this snapshot.
0 tracked postings mention remote work.
| Company | Employees |
|---|---|
| Novocure ↗ | 1,320 |
| Vayyar ↗ | 330 |
| biotechnology general ↗ | 300 |
| Protalix BioTherapeutics ↗ | 197 |
| RedHill Biopharma ↗ | 183 |
| Nanox ↗ | 180 |
| Tag Medical Products ↗ | 165 |
| UroGen Pharma ↗ | 150 |
921 founders and chief executives across 675 companies.
Current CEO of Insightec
Founder Tumor Treating Fields & Novocure.
Ex-Intel, Envara. Ben-Gurion University MSc
Ex-Opko Biologics. BGU Negev, Israel PhD
Ex-CEO XTL Biopharmaceuticals. Hebrew University of Jerusalem Israel BA, New York Universitys Stern School of Business MBA
8400, IATI, ex-ISL. Technion Israel Institute of Technology BA 2004, MSc 2006, Weizmann Institute of Science PhD 2010
Ex-Ph.D. in Biomedical Engineering Tel-Aviv University
Founder Augmedics, ex-Volume Elements. University of Cambridge MSc 2008, University of Oxford PhD 2011
Founder Ossio, ex-IDF Institute for Military Physiology. Columbia University 2004, Technion - Israel Institute of Technology 2006
ex-Mediline, PharmaSwiss, Eli Lilly. Tel Aviv University BA 1998, INSEAD MBA 2001
Bluewind Medical, ex-Direct Flow Medical, ex-White Pine Medical, Bowling Green State University, 1978
ex- Co-Founder NeuroVir Therapeutics, enon Pharmaceuticals, Aspreva Pharmaceuticals. University of Gottingen 2014
219 profiles with education records.
10 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
336,757 articles in the measured 12-month window.
Life Sciences coverage across Israel · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 36,642 |
| 2021Q3 | 26,153 |
| 2021Q4 | 23,013 |
| 2022Q1 | 23,845 |
| 2022Q2 | 22,151 |
| 2022Q3 | 21,949 |
| 2022Q4 | 24,014 |
| 2023Q1 | 27,299 |
| 2023Q2 | 26,128 |
| 2023Q3 | 25,676 |
| 2023Q4 | 155,550 |
| 2024Q1 | 89,565 |
| 2024Q2 | 94,214 |
| 2024Q3 | 75,153 |
| 2024Q4 | 87,286 |
| 2025Q1 | 74,575 |
| 2025Q2 | 82,789 |
| 2025Q3 | 76,260 |
| 2025Q4 | 45,626 |
| 2026Q1 | 104,625 |
Article volume measures coverage, not market sales.
962 recorded company events across 110 companies; percentages use that event total.
Life Sciences coverage across Israel · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
Life Sciences coverage across Israel
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| diplomatic strategies | 5,877 | 2,757 | 113% |
| national security strategy | 5,781 | 1,415 | 309% |
| foreign policy analysis | 5,329 | 2,315 | 130% |
| multilateral diplomacy | 4,355 | 1,702 | 156% |
| geopolitical alliances | 4,344 | 2,310 | 88% |
| diplomatic engagements | 3,314 | 1,224 | 171% |
| nuclear proliferation | 3,275 | 608 | 439% |
| oil price volatility | 2,796 | 1,341 | 109% |
| humanitarian corridors | 1,920 | 1,326 | 45% |
| diplomatic protocol | 1,884 | 783 | 141% |
| ceasefire violations | 1,904 | 3,733 | -49% |
| hostage negotiations | 1,019 | 2,618 | -61% |
| school bombings | 1,137 | 1,811 | -37% |
| campus police | 283 | 1,391 | -80% |
| campus safety | 297 | 1,363 | -78% |
Life Sciences coverage across Israel
aerial bombardments, accidental bombings, diplomatic strategies
80.9% critical · 9.3% positivehigher education funding, school funding battles, currency intervention policies
67.0% critical · 26.6% positiveearnings report, oil price volatility, quarterly financials
44.8% critical · 38.9% positiveLife Sciences coverage across Israel. Topic labels describe recorded classifications and can include broad context.
53,147 papers in the recorded worldwide scope.
Tone counts: 42,568 positive · 8,415 neutral · 2,164 negative.
Landmark: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term prob
Landmark: Genomic responses in mouse models poorly mimic human inflammatory diseases
Landmark: Copper-Zinc Superoxide Dismutase (SOD1) Is Released by Microglial Cells and Confers Neuroprotection against 6-OHDA Neurotoxicity
Common problems researchers identify · 0117.3% of this theme group
Researchers highlight ecological and technical hurdles in using microbes and plant biomass for renewable fuels and bioproducts.
Biofuel (41) · Synthetic biology (53) · Biomass (45) · Biorefinery (28)
A review on the plant microbiome: Ecology, functions, and emerging trends in microbial application
Biofertilizers: An ecofriendly technology for nutrient recycling and environmental sustainability
| Year | Share index |
|---|---|
| 2022 | 60.6 |
| 2023 | 59.3 |
| 2024 | 61.9 |
| 2025 | 67.0 |
Common problems researchers identify · 0216.8% of this theme group
Papers discuss microbial hazards, nutritional impacts, and safety concerns across the food production chain.
Food safety (130) · Food processing (74) · Food products (50) · Human health (90)
Microbial Risks in Food: Evaluation of Implementation of Food Safety Measures
Nutritional quality and processing of plant proteins for healthy and sustainable foods
| Year | Share index |
|---|---|
| 2022 | 70.2 |
| 2023 | 72.4 |
| 2024 | 77.4 |
| 2025 | 99.2 |
Common problems researchers identify · 0315.8% of this theme group
Studies examine obstacles in controlling gene expression, mRNA stability, and cell‑culture models for biomedical applications.
Messenger RNA (28) · Gene (44) · Cell culture (23) · Gene expression (24)
Analysis of Cancer Metabolism by Imaging Hyperpolarized Nuclei: Prospects for Translation to Clinical Research
Evolution of Approaches to the Development, Life Cycle Control, and Interchangeability of Veterinary Biosimilars Based on Hemoproteins (with
| Year | Share index |
|---|---|
| 2022 | 2510.1 |
| 2023 | 2495.8 |
| 2024 | 2199.0 |
| 2025 | 1697.8 |
Common problems researchers identify · 0415.4% of this theme group
Research points to inefficiencies in fertiliser use, germplasm resources, and breeding strategies for resilient crops.
Agriculture (208) · Crop (84) · Food security (86) · Germplasm (39)
Revisiting fertilisers and fertilisation strategies for improved nutrient uptake by plants
Breeding for nutrient use efficiency in crop plants: Mechanistic insights, genetic determinants, and emerging breeding technologies
| Year | Share index |
|---|---|
| 2022 | 1635.2 |
| 2023 | 1667.4 |
| 2024 | 1799.9 |
| 2025 | 2026.9 |
Common problems researchers identify · 0515.3% of this theme group
Works identify gaps in integrated pest management, host resistance, and pathogen‑vector dynamics.
Fungicide (44) · Integrated pest management (54) · Host (41) · Disease management (32)
Innate Immunity in Plants: An Arms Race Between Pattern Recognition Receptors in Plants and Effectors in Microbial Pathogens
Insect-Borne Plant Pathogens and Their Vectors: Ecology, Evolution, and Complex Interactions
| Year | Share index |
|---|---|
| 2022 | 27.8 |
| 2023 | 29.2 |
| 2024 | 27.8 |
| 2025 | 37.2 |
Common problems researchers identify · 069.9% of this theme group
Literature flags rising resistance in humans, livestock, and the environment and the need for stewardship.
Antibiotic resistance (301) · Antimicrobial (164) · Antibiotics (126) · Drug resistance (49)
Antimicrobial resistance in humans, livestock and the wider environment
Antimicrobial use and resistance
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Common problems researchers identify · 079.4% of this theme group
Papers reveal basic uncertainties in metabolic pathways, enzyme functions, and molecular mechanisms.
Order (19) · NAD+ kinase (11) · Human being (12) · Sodium (11)
Modalidade, polaridade e legibilidade em resumos académicos: uma análise comparativa multidisciplinar
Obiteljska grupna konferencija: prilika za građansko pravosuđe?
| Year | Share index |
|---|---|
| 2022 | 18.4 |
| 2023 | 21.9 |
| 2024 | 17.8 |
| 2025 | 12.5 |
Cautions · 0121.5% of this theme group
Authors caution about in‑vitro and in‑vivo models showing stress responses to nanomaterials and chemicals.
In vivo (32) · Flow cytometry (16) · In vitro (27) · Oxidative stress (19)
Effects of Microplastics on Cell Viability, Phagocytic Activity and Oxidative Stress in Human Peripheral Blood Mononuclear Cells
Cell Painting for cytotoxicity and mode-of-action analysis in primary human hepatocytes
| Year | Share index |
|---|---|
| 2022 | 1034.9 |
| 2023 | 1110.3 |
| 2024 | 911.7 |
| 2025 | 818.5 |
Cautions · 0214.6% of this theme group
Studies warn of uncertainties when applying genomic selection to breeding and sustainable animal feed development.
Agriculture (45) · Selection (26) · Production (28) · Trait (16)
Genomic selection in plant breeding: from theory to practice
Future Directions for Sustainable Poultry Feeding and Product Quality: Alternatives from Insects, Algae and Agro-Industrial Fermented By-Pro
| Year | Share index |
|---|---|
| 2022 | 1437.3 |
| 2023 | 1478.4 |
| 2024 | 1637.4 |
| 2025 | 1817.4 |
Cautions · 0313.9% of this theme group
Research emphasizes the need for rigorous evaluation of bioactive feed compounds and their health impacts.
Feed additive (27) · Animal feed (28) · Feed conversion ratio (32) · Health benefits (30)
Natural Bioactive Compounds as Feed Additives: Strategies for Sustainable and Functional Livestock Production
The impact of substituting animal with plant protein foods in adults’ self-selected diets on environmental, nutritional, and health outcomes
| Year | Share index |
|---|---|
| 2022 | 22.2 |
| 2023 | 20.9 |
| 2024 | 17.3 |
| 2025 | 18.2 |
Cautions · 0413.6% of this theme group
Papers discuss gaps in safety data and regulatory frameworks for emerging food additives and contaminants.
Food safety (66) · Hygiene (21) · Contamination (29) · Food contaminant (20)
Caffeine (1, 3, 7‐trimethylxanthine) in Foods: A Comprehensive Review on Consumption, Functionality, Safety, and Regulatory Matters
Insect-derived food colorants: Chemistry, applications, safety, and regulatory perspectives
| Year | Share index |
|---|---|
| 2022 | 91.3 |
| 2023 | 89.1 |
| 2024 | 95.4 |
| 2025 | 105.8 |
Cautions · 0513.5% of this theme group
Works highlight incomplete understanding of gene‑level damage responses and implications for disease diagnostics.
Gene (41) · DNA damage (26) · DNA repair (13) · Gene expression (20)
Comparative analysis of microRNA expression in serum and plasma in patients screened for BRCA1 or BRCA2 mutations
Homologous recombination deficiency in primary ER-positive and HER2-negative breast cancer
| Year | Share index |
|---|---|
| 2022 | 2415.6 |
| 2023 | 2417.4 |
| 2024 | 2125.5 |
| 2025 | 1613.8 |
Cautions · 0611.7% of this theme group
Authors note the complex interplay of antibiotics, biocides, and metals driving resistance in pathogens.
Antibiotic resistance (59) · Antibiotics (47) · Antimicrobial (38) · Bacteria (26)
Antibiotic use in food animals worldwide, with a focus on Africa: Pluses and minuses
Co-Selection of Resistance to Antibiotics, Biocides and Heavy Metals, and Its Relevance to Foodborne Pathogens
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Cautions · 0711.3% of this theme group
Literature points to difficulties in dosing strategies and biological control integration to curb resistance.
Pesticide (34) · Integrated pest management (21) · PEST analysis (30) · Biological pest control (20)
The use of fungal entomopathogens as endophytes in biological control: a review
Managing pesticide resistance by changing the applied dose: a modeling analysis incorporating pesticide persistence and including low-dose m
| Year | Share index |
|---|---|
| 2022 | 66.9 |
| 2023 | 65.3 |
| 2024 | 66.9 |
| 2025 | 75.8 |
Opportunities · 0117.4% of this theme group
Research explores novel antibodies, fluorescence methods, and flow cytometry for in‑vivo diagnostics and therapy.
Antibody (70) · In vivo (81) · Fluorescence (40) · Flow cytometry (50)
Figure 4 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcom
Preparation, Characterization, and Binding Mechanism of Nanobodies Targeting Multiple Serotypes of <i>Salmonella</i>
| Year | Share index |
|---|---|
| 2022 | 561.4 |
| 2023 | 615.1 |
| 2024 | 467.1 |
| 2025 | 455.3 |
Opportunities · 0217.2% of this theme group
Papers present promising approaches using knockdown, up‑regulation, and apoptosis control to treat cancers and metabolic disorders.
Downregulation and upregulation (106) · Apoptosis (80) · Gene knockdown (103) · Cell growth (43)
Fat Mass and Obesity‐Associated Protein Contributes to Tumorigenesis and Drug Resistance of Diffuse Large B‐Cell Lymphoma by Suppressing <sc
RasGRP3 Promotes RAP1B Activity to Inhibit Endothelial Inflammation and Alleviate Atherosclerosis in High-Fat Diet-Fed ApoE−/− Mice
| Year | Share index |
|---|---|
| 2022 | 364.0 |
| 2023 | 394.7 |
| 2024 | 257.4 |
| 2025 | 261.8 |
Opportunities · 0314.6% of this theme group
Studies highlight bioactive ingredients, antioxidants, and sustainable protein sources to improve nutrition and aging.
Health benefits (78) · Functional food (61) · Ingredient (48) · Antioxidant (69)
Plant-based functional foods for healthy aging: current trends, bioactive compounds, and future perspectives
PLANT-BASED PROTEINS: SOURCES, EXTRACTION METHODS AND FUNCTIONAL PERSPECTIVES FOR THE SUSTAINABLE FOOD INDUSTRY
| Year | Share index |
|---|---|
| 2022 | 26.7 |
| 2023 | 26.2 |
| 2024 | 27.1 |
| 2025 | 45.2 |
Opportunities · 0413.7% of this theme group
Research focuses on DNA methylation patterns, mRNA engineering, and detection platforms for precision medicine.
Gene (164) · DNA methylation (60) · Messenger RNA (76) · DNA damage (55)
Convergent DNA methylation abnormalities at enhancers and bivalent promoters in human growth disorders
Stimuli-ResponsiveFusion of Binary-Star IntelligentDNA System for the Signal-On Amplification Detection of Cancer-RelatedmiRNA
| Year | Share index |
|---|---|
| 2022 | 2397.7 |
| 2023 | 2377.6 |
| 2024 | 2114.7 |
| 2025 | 1613.7 |
Opportunities · 0513.5% of this theme group
Works investigate plant‑derived antimicrobials, resistance‑modifying agents, and microbial metabolites for animal health.
Antimicrobial (126) · Antibiotic resistance (66) · Biological pest control (54) · Bacteria (87)
Plants as sources of new antimicrobials and resistance-modifying agents
Postbiotics: Multifunctional Microbial Products Transforming Animal Health and Performance
| Year | Share index |
|---|---|
| 2022 | 524.8 |
| 2023 | 510.4 |
| 2024 | 554.5 |
| 2025 | 649.8 |
Opportunities · 0611.9% of this theme group
Papers detail quantitative trait loci, germplasm analysis, and selection methods to boost agricultural productivity.
Germplasm (71) · Trait (52) · Quantitative trait locus (40) · Selection (53)
Evaluation of Genetic Variability and Trait Interrelationships Using Advanced Wheat Lines to Increase Yield
GENETIC VARIABILITY ANALYSIS FOR YIELD AND RELATED TRAITS IN WHEAT (TRITICUM AESTIVUM L.) MUTANT GENOTYPES
| Year | Share index |
|---|---|
| 2022 | 53.0 |
| 2023 | 45.3 |
| 2024 | 39.2 |
| 2025 | 40.8 |
Opportunities · 0711.6% of this theme group
Research showcases microbial fermentation and by‑product valorisation to create renewable chemicals and fuels.
Biomass (67) · Sustainability (77) · Agriculture (102) · Biofuel (35)
Microbial Fermentation: A Sustainable Strategy for Producing High-Value Bioactive Compounds for Agriculture, Animal Feed, and Human Health
Bioactive Compounds From Agri‐Food By‐Products: Advancements in Environmental Sustainability and Bioeconomic Progress
| Year | Share index |
|---|---|
| 2022 | 1514.8 |
| 2023 | 1566.1 |
| 2024 | 1742.6 |
| 2025 | 1980.2 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Descriptive | 40.2% | 17.3% |
| Promising | 30.4% | 37.4% |
| Breakthrough | 14.1% | 26.2% |
| Problem-identifying | 8.3% | 9.7% |
| Cautionary | 3.5% | 4.5% |
| Comparative | 2.4% | 3.9% |
| Critical | 1.0% | 1.0% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceSARS-CoV-2 wastewater genomic surveillance: approaches, challenges, and opportunities | 87 | 0.21% | 25 (28.7%) | 0.21% |
| Hardware, e-waste & supply chainFate and Transport of Antibiotic Residues and Antibiotic Resistance Genes following Land Application of Manure Waste | 61 | 0.15% | 4 (6.6%) | 0.15% |
| Bias & fairnessGeographic Prevalence Heterogeneity Creates Unavoidable Fairness-Accuracy Trade-offs in Antimicrobial Resistance Predict | 12 | 0.03% | 2 (16.7%) | 0.03% |
| Safety & misusePublic perceptions and information sources on genetically modified organisms in Kenya | 3 | 0.01% | 3 (100.0%) | 0.01% |
| Energy & datacenter footprintIntegration of GWAS and WGCNA Identifies PUE‐Related Gene <i>TaERF112</i> in Wheat | 1 | 0.0% | 0 (0.0%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
| Carbon & emissions of compute | 0 | 0.0% | 0 (%) | 0.0% |
| Labour & data work | 0 | 0.0% | 0 (%) | 0.0% |
| Concentration of compute power | 0 | 0.0% | 0 (%) | 0.0% |
Research orientation and citation rankings describe the covered collection. Its recorded publication dates do not support an overall publication-volume trend.
Institution and researcher rankings use citations to their covered work. Research scope: worldwide. This may be broader than the company geography.
Published patent filings in the recorded source window.
Company counts, hiring and disclosed funding across the recorded hubs.
27.1% across the displayed hubs
6 companies hiring · $972.2M disclosed funding
Explore companies in Tel Aviv ↗
17.9% across the displayed hubs
2 companies hiring · $815.4M disclosed funding
Explore companies in Jerusalem ↗
12.8% across the displayed hubs
5 companies hiring · $639.4M disclosed funding
Explore companies in Rehovot ↗
11.1% across the displayed hubs
0 companies hiring · $873.5M disclosed funding
Explore companies in Haifa ↗10.1% across the displayed hubs
3 companies hiring · $499.8M disclosed funding
Explore companies in Ness Ziona ↗
8.7% across the displayed hubs
3 companies hiring · $728.1M disclosed funding
Explore companies in Herzliya ↗
6.3% across the displayed hubs
5 companies hiring · $94.5M disclosed funding
Explore companies in Netanya ↗6.1% across the displayed hubs
2 companies hiring · $410.9M disclosed funding
Explore companies in Petah Tikva ↗Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 31 August 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗
